Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/11/2021 | 07:35am EST

Knight Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was CAD 73.34 million compared to CAD 45.24 million a year ago. Net loss was CAD 8.59 million compared to net income of CAD 18.09 million a year ago. Basic loss per share from continuing operations was CAD 0.07 compared to basic earnings per share from continuing operations of CAD 0.14 a year ago. Diluted loss per share from continuing operations was CAD 0.07 compared to diluted earnings per share from continuing operations of CAD 0.14 a year ago. For the nine months, sales was CAD 185.21 million compared to CAD 144.33 million a year ago. Net income was CAD 23.98 million compared to CAD 33.83 million a year ago. Basic earnings per share from continuing operations was CAD 0.19 compared to CAD 0.26 a year ago. Diluted earnings per share from continuing operations was CAD 0.19 compared to CAD 0.26 a year ago.


ę S&P Capital IQ 2021
All news about KNIGHT THERAPEUTICS INC.
01/06Knight Therapeutics Announces Approval of Breast Cancer Drug, Halaven, in Colombia
MT
01/06KNIGHT THERAPEUTICS BRIEF : Announces Approval of Halaven in Colombia
MT
01/06Knight Therapeutics Inc. Announces Approval of Halaven« in Colombia
AQ
01/06Knight Therapeutics Inc. Announces Approval of Halaven« in Colombia
CI
01/05Knight Therapeutics Inc. Announces Approval of Lenvima in Colombia
AQ
01/04Knight Therapeutics Reports Approval of Lenvima in Colombia
MT
01/04Knight Therapeutics Inc. Announces Approval of Lenvima« in Colombia
AQ
01/04Knight Therapeutics Inc. Announces Approval of Lenvima« in Colombia
CI
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
GL
More news
Financials
Sales 2021 247 M 195 M 195 M
Net income 2021 22,8 M 18,0 M 18,0 M
Net Debt 2021 - - -
P/E ratio 2021 26,6x
Yield 2021 -
Capitalization 627 M 494 M 494 M
Capi. / Sales 2021 2,54x
Capi. / Sales 2022 2,17x
Nbr of Employees 679
Free-Float 80,1%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 5,32 CAD
Average target price 7,80 CAD
Spread / Average Target 46,6%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
James Charles Gale Lead Independent Director
Robert N. Lande Independent Director
Sector and Competitors